Skip to main content

Our Mission

To improve the lives of people impacted by hypoparathyroidism through education, support, research, and advocacy. Learn more and get involved.


Unexpected manufacturing disruptions expected as early as November 21, 2020

AZP-3601 is currently in development for the treatment of hypoparathyroidism

Plans move forward with phase 3 PaTHway trial

The study will be conducted at the National Institutes of Health.

OCT 23 - 25. Live informative lectures on HypoPARA with knowledgeable doctors and specialists!